![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
20
Dong Bang Future Tech & Life Co., Ltd. Hwaseong-si Kr, based in South Korea, is a pharmaceutical company.
One of their significant offerings is Sitagliptin phosphate monohydrate, supported by a 'Valid' Certificate of Suitability (CEP) with the number CEP 2020-028 - Rev 02
This Chemical Type CEP, issued on June 28, 2024, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2778 associated with this CEP further emphasizes